AKT1 and cancer: Notably, myo-inositol targets critical cancer liabilities43–45 by: (i) inhibiting pRB phosphorylation and subsequently blocking the cell cycle; (ii) reducing PI3K, Akt, ERK and NF-kB and (iii) impairing invasiveness43–45.